Advertisement


Pierfranco Conte, MD, on Early-Stage Triple-Negative Breast Cancer: Trial Update on Avelumab as Adjuvant Treatment

2024 ASCO Annual Meeting

Advertisement

Pierfranco Conte, MD, of the University of Padua, discusses phase III findings from the A-BRAVE trial, which was designed to evaluate the efficacy of avelumab, an anti–PD-L1 antibody, as adjuvant treatment for patients with early-stage triple-negative breast cancer who are at high risk (LBA500).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The A-BRAVE trial was an academic driven trial conducted in patients at high risk with early triple negative breast cancer. The purpose of the study was to improve the prognosis of these patients by selecting subgroup of patients at particularly high risk of relapse. In the study, we have randomized two strata of patients. One was patients who went to surgery upfront, and after surgery had a diagnosis of advanced stages of disease, high positivity, axillary lymph load, large tumor size. The second stratum were the patients who had received neoadjuvant chemotherapy and had surgery after neoadjuvant chemotherapy, still had invasive residual disease in the breast and/or in the axillary lymph nodes. The primary end points of the study were disease-free survival in the entire study population, and the disease-free survival in the post-neoadjuvant group, which included 82% of a total population. We didn't meet the primary end points, because we did observe a difference in favor of avelumab in disease-free survival, a 5% improvement at three years in disease-free survival in the whole population, and a 6% improvement in the post-neoadjuvant population. But this was not statistically significant, hazard ratio was 0.8, p-value 0.17. We did observe on the contrary, a statistically significant difference in overall survival in the entire study. Population at three years the advantage in overall survival for Avelumab was 8.5%, the hazard ratio 0.66, which means a 34% reduction in the risk of death, the p-value 0.035. We did also perform a postdoc exploratory analysis, try to understand why we are seeing a larger benefit in overall survival than disease-free survival, and the analysis was on distant disease-free survival. And again, we did observe a significant advantage for Avelumab, 7.5% improvement at three years in distant disease-free survival, hazard ratio 0.7, p-value 0.027. We do know that in many countries today standard of care for high-risk, early triple negative disease is neoadjuvant chemotherapy plus Pembrolizumab. So Pembrolizumab is given to all these patients before surgery, and also is continued after surgery, independently from the pathological response observed at surgery. And this is, as I said before, standard recommended by international and also national guidelines in Italy. There are aware still patients who do not receive Pembro if a neoadjuvant situation. Patients who have a smaller tumor size, clinically negative axillary lymph nodes, patients for whom physicians may, or might, have some concern about the tolerability of a treatment. So there are still patients who receive neoadjuvant chemotherapy without Pembro. Many of these patients fortunately receive a pathological [inaudible 00:04:00] response, but still some of them, 40 to 50%, have residual invasive disease, and they think that for these patients avelumab will be a good option. Highly effective in terms of distant disease-free survival, effective in terms of overall survival, and also tolerability was quite good. Now of course, this is the first presentation of the study, because the study was an event-driven study. We will follow up the patients longer, by sure. And there are many translational studies ongoing, because we have collected tumor samples, blood, plasma, and feces by all these patients. So, we will have a lot of translational research trying to understand who are the patients who benefit more, and who are the patients who unfortunately still relapse in spite of avelumab?

Related Videos

Pancreatic Cancer

Belinda Lee, MBBS, on Early-Stage Pancreatic Cancer: New Data on Guiding Adjuvant Chemotherapy

Belinda Lee, MBBS, of Peter MacCallum Cancer Centre, Northern Health, Walter & Eliza Hall Institute, Melbourne, discusses findings from the AGITG DYNAMIC-Pancreas trial on the potential role of serial circulating tumor DNA testing after upfront surgery to guide adjuvant chemotherapy for early-stage disease (Abstract 107).

Leukemia

Mazyar Shadman, MD, MPH, on Chronic Lymphocytic Leukemia: Update on BTK Inhibitors

Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center, discusses a network meta-analysis showing that zanubrutinib appears to be the most efficacious Bruton’s tyrosine kinase (BTK) inhibitor for patients with high-risk relapsed or refractory chronic lymphocytic leukemia. It offers delayed disease progression and favorable survival and response, compared with alternative BTK inhibitors (Abstract 7048).

 

Breast Cancer

Fabrice Andre, MD, PhD, on Breast Cancer: Interim Analysis From DESTINY-Breast07

Fabrice Andre, MD, PhD, of Gustave Roussy and the Université Paris-Saclay, discusses a dose-expansion interim analysis of trastuzumab deruxtecan (T-DXd) monotherapy and T-DXd plus pertuzumab in patients with previously untreated HER2-positive metastatic breast cancer (Abstract 1009).

Kidney Cancer

Brian I. Rini, MD, on Renal Cell Carcinoma: Exploratory Biomarker Results

Brian I. Rini, MD, of Vanderbilt Ingram Cancer Center, discusses phase III findings of the KEYNOTE-426 study of pembrolizumab plus axitinib vs sunitinib for patients with advanced renal cell carcinoma. He details the exploratory biomarker results, including RNA sequencing, whole-exome sequencing, and PD-L1 (Abstract 4505).

Bladder Cancer

Thomas Powles, MD, PhD, and Jonathan E. Rosenberg, MD, on Urothelial Carcinoma: The DESTINY-Pan Tumor02 Study and New Findings on Sacituzumab Govitecan

Thomas Powles, MD, PhD, of Barts Cancer Institute and the University of London, and Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discuss clinical outcomes of sacituzumab govitecan-hziy after prior exposure to enfortumab vedotin-ejfv in patients with metastatic urothelial carcinoma, as well as the safety and efficacy of fam-trastuzumab deruxtecan-nxki in patients with HER2-expressing bladder tumors (Abstracts 4502 and 4509).

Advertisement

Advertisement




Advertisement